Elan has reported a $60.7 million third quarter loss on revenues of $340 million versus $484.3 million in the same quarter last year.
The company said on total cash balances as of September 30th were $632.9 million and added that this figure, which is considered key to the company's recovery plan and its need to pay off $3.0 billion in debt, should exceed $1 billion when deals for its Abelcet and Actiq drugs are closed.
It also said its Antegren and Prialt products, as well as its Alzheimer treatment, were progressing "as targeted in the recovery plan".
Elan had already divulged many of the key points of itsresults in a trading statement last month in which it flagged that it would take a $542 million charge for the period.
Elan has seen its market value drop to just over half a billion dollars from a peak of $22 billion in June of last year amid concerns about its bookkeeping arrangements.